FDA Approves Nasal Spray for Depression
The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to ...
Milk Recall Update As FDA Sets Risk Class Over Spoilage Fears
19,688 cases of the milk overall were recalled, 8,654 of which had an expiry date of 3/3/2025, 7,385 with expiry date 3/4/2025, 1,781 with expiry date 3/6/2025, and 1,868 with expiry date 3/7/2025.
Managed Healthcare Executive7h
FDA Approves Spravato Nasal Spray as a Standalone Treatment for Major Depressive Disorder
One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...
FDA proposes mandatory front-of-package nutrition labels to combat spike in chronic diseases
The U.S. Food and Drug Administration (FDA) is demanding increased, in-your-face food transparency when it comes to nutrition ...
The American Journal of Managed Care20h
Esketamine Approved by FDA as First Monotherapy for Treatment-Resistent Depression
Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD ...
FDA: This common cookware may contaminate your food; here’s why
The U.S. Food & Drug Administration (FDA) would like for people to be aware of the potential risks of using common cooking ...
Targeted Oncology4d
FDA Grants Fast Track Designation to LOAd703 in Pancreatic Cancer
LOAd703, an oncolytic adenovirus with transgenes for 4-1BBL and TMZ-CD40L, has received FDA fast track designation for ...
Healio4d
FDA approves sale of Zyn nicotine pouches following extensive review
The FDA announced it has authorized the marketing of 20 Zyn nicotine pouch products, citing their greater health benefits vs.
Becker's Hospital Review4d
FDA spotlights risks in medical device supply chain
The FDA warned the nation about the growing vulnerability of the medical device supply chain and its effects on public health, particularly among pediatric patients, in a Jan. 16 news release.
Targeted Oncology5d
FDA Issues Complete Response Letter for Tab-cel in EBV+ PTLD
The FDA has issued a complete response letter to the biologics license application seeking the approval of tabelecleucel for ...
Managed Healthcare Executive5d
FDA Approves Lilly’s Omvoh for Crohn's Disease, Second Indication
More than half (53%) of patients reached remission after one year of Omvoh treatment and 46% experienced healing of the ...
For first time, FDA approves marketing of nicotine pouch products
The U.S. Food and Drug Administration on Thursday okayed the marketing of 20 Zyn nicotine pouch products after undertaking an ...